8-K: Curis Reports Q2 2025 Results, Advances Emavusertib

Curis, Inc. announced its second quarter 2025 financial results, reporting a reduced net loss and increased revenue, alongside significant clinical progress for its lead asset, emavusertib, in lymphoma and leukemia studies.

Summary

• Net loss for the second quarter of 2025 decreased to $8.6 million, or $0.68 per share, compared to $11.8 million, or $2.03 per share, for the same period in 2024.
• Revenues for Q2 2025 increased to $2.7 million from $2.5 million in Q2 2024, primarily from Erivedge royalty revenues.
• Research and development expenses decreased to $7.5 million in Q2 2025 from $10.3 million in Q2 2024, driven by lower employee-related, research, consulting, and clinical costs.
• General and administrative expenses also decreased to $3.5 million in Q2 2025 from $4.8 million in Q2 2024, due to lower employee-related and legal costs.
• Cash and cash equivalents totaled $10.1 million as of June 30, 2025, with approximately 10.7 million shares of common stock outstanding.
• A registered direct offering and concurrent private placement completed in July 2025 raised $6.0 million, extending the cash runway into the first quarter of 2026.
• Enrollment continues for relapsed/refractory Primary Central Nervous System Lymphoma (R/R PCNSL) patients in the TakeAim Lymphoma study, supporting accelerated approval filings in the US and EU.
• Emavusertib has received orphan drug designation from both the FDA and EMA for PCNSL.
• A new proof-of-concept clinical study of emavusertib in combination with a BTK inhibitor in 20-30 patients with relapsed/refractory Chronic Lymphocytic Leukemia (R/R CLL) is planned to begin enrollment later this year, aiming for time-limited treatment.
• Enrollment was completed in the TakeAim Leukemia Phase 1/2 study of emavusertib monotherapy in R/R Acute Myeloid Leukemia (AML) or R/R Myelodysplastic Syndrome (MDS).
• Discussions are ongoing with clinical trial investigators and key opinion leaders regarding the design of a head-to-head registrational trial of emavusertib versus gilteritinib in R/R AML and a Phase 1/2 study in frontline high-risk MDS (hrMDS) in combination with azacitidine.
• An ongoing triplet study evaluating emavusertib, venetoclax, and azacitidine in frontline AML is expected to yield data at the 67th American Society of Hematology (ASH) Annual Meeting in December.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to significant clinical progress across multiple indications for emavusertib, including advancement towards accelerated approvals and expansion into new patient populations with high unmet needs. Financial results show improved efficiency with reduced net loss and expenses, and a recent capital raise extended the cash runway. However, the short cash runway into Q1 2026 and the stated need for substantial additional capital introduce a notable element of financial risk and uncertainty.

Positives

• Net loss significantly reduced to $8.6 million in Q2 2025 from $11.8 million in Q2 2024, indicating improved financial efficiency.
• Revenue increased to $2.7 million in Q2 2025 from $2.5 million in Q2 2024, driven by Erivedge royalty revenues.
• Research and development expenses decreased by 27.7% year-over-year, reflecting cost management.
• General and administrative expenses decreased by 26.5% year-over-year, contributing to reduced operating costs.
• Continued enrollment in the TakeAim Lymphoma study for PCNSL patients is progressing towards accelerated approval filings in the US and EU.
• Emavusertib received Orphan Drug Designation from both the FDA and EMA for PCNSL, which can expedite development and provide market exclusivity.
• The addition of a new proof-of-concept clinical study for emavusertib in combination with a BTK inhibitor in R/R CLL patients expands the potential market and addresses a significant unmet need for time-limited treatment.
• Completed enrollment in the TakeAim Leukemia Phase 1/2 study for R/R AML/MDS, moving closer to potential registrational trials.
• Engagement with KOLs on the design of a head-to-head registrational trial in R/R AML and a Phase 1/2 study in frontline high-risk MDS indicates a clear development path for emavusertib.
• The recent registered direct offering and private placement raised $6.0 million, extending the cash runway into Q1 2026, providing short-term financial stability.

Negatives

• Despite improvements, the company continues to report a net loss of $8.6 million for Q2 2025 and $19.2 million for the six months ended June 30, 2025.
• Other expense increased to $0.3 million in Q2 2025 compared to other income of $0.7 million in Q2 2024, primarily due to decreased interest income and increased expense related to the sale of future royalties.
• The cash runway is only extended into the first quarter of 2026, indicating a need for substantial additional capital in the near future to fund ongoing operations and development.
• The company's total stockholders' deficit increased to $(13.986) million as of June 30, 2025, from $(5.998) million as of December 31, 2024, reflecting accumulated losses.

Risks

• Adverse results, delays, and/or failures in drug development programs, potentially preventing successful advancement of drug candidates.
• Drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies, or may never achieve the requisite regulatory approvals.
• Failure to achieve projected timelines for enrolling patients and submitting regulatory filings for emavusertib in PCNSL and/or other potential indications.
• Safety and efficacy data results from the TakeAim Lymphoma study of emavusertib in PCNSL may not be sufficient for conditional marketing authorization from the EMA or accelerated approval from the FDA.
• Favorable results seen in preclinical studies and early clinical trials of drug candidates may not be replicated in later trials.
• Dependence on the success of emavusertib, with any delays in its development potentially having a material adverse effect on the business.
• No guarantee that the collaboration agreement with Aurigene will continue for its full term, or that Curis or its collaborators will maintain necessary financial and other resources.
• Regulatory authorities may delay or restrict Genentech's and/or Roche's ability to continue commercializing Erivedge.
• Development of competing drugs superior to Erivedge or the emergence of generic versions.
• Risks related to the agreement with Oberland Capital concerning the transfer and encumbrance of Erivedge royalties, including potential loss of retained rights, repurchase obligations, and inhibited future arrangements.
• Requirement for substantial additional capital to fund the business, as existing cash resources are insufficient to support current operations within the next 12 months.
• Inability to obtain sufficient funding could force delays, reductions in scope, or elimination of emavusertib development, impacting business prospects and ability to continue operations.
• Substantial competition in the biotechnology and oncology sectors.
• Risk of potential adverse decisions made by regulatory authorities (FDA, EMA), investigational review boards, and publication review bodies.
• Inability to obtain or maintain necessary patent protection, leading to expensive and time-consuming patent litigation.
• Unstable market and economic conditions, natural disasters, public health crises, political crises, and other events outside of control could significantly disrupt operations or ability to raise capital, including maintaining Nasdaq listing.

Future Outlook

The company anticipates providing additional data for relapsed/refractory Primary Central Nervous System Lymphoma (R/R PCNSL) patients from the TakeAim Lymphoma study later this year, with ongoing enrollment supporting accelerated approval filings in the US and EU. Enrollment for a new proof-of-concept clinical study of emavusertib in combination with a BTK inhibitor in R/R Chronic Lymphocytic Leukemia (CLL) patients is expected to begin later this year, aiming for time-limited treatment. Data from the ongoing triplet study evaluating emavusertib, venetoclax, and azacitidine in frontline Acute Myeloid Leukemia (AML) is expected at the 67th ASH Annual Meeting in December. The company projects its existing cash and cash equivalents, combined with the $6.0 million from the July 2025 offerings, will fund operations into the first quarter of 2026, indicating a need for substantial additional capital thereafter.

Management Comments

• "We are pleased with our progress in the TakeAim Lymphoma study and are continuing to enroll PCNSL patients in both Part B (BTKi-experienced patients) and Part C (BTKi-nave patients) to enable accelerated approval filings in the US and EU. We look forward to providing updated data later this year."
• "We are also excited to add a clinical study of emavusertib in combination with a BTK inhibitor in Chronic Lymphocytic Leukemia, as part of our strategy to expand across CLL and NHL and bring this novel treatment option to broader patient populations with unmet needs. For CLL patients in particular, this could represent a fundamental change in the treatment paradigm, with the potential of an emavusertib-BTKi combination to enable time-limited treatment. We look forward to beginning enrollment later this year."

Industry Context

This announcement highlights Curis's continued focus on developing emavusertib, an IRAK4 inhibitor, for hematologic malignancies, a highly competitive but high-need area within oncology. The strategy to expand into Chronic Lymphocytic Leukemia (CLL) with a combination therapy targeting time-limited treatment represents a significant potential shift from current lifelong BTK inhibitor therapies, addressing a key patient unmet need. Progress in Primary Central Nervous System Lymphoma (PCNSL) and Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) positions emavusertib as a multi-indication asset. The emphasis on accelerated approval pathways and registrational trial designs reflects the industry's drive to bring novel therapies to market efficiently for severe diseases.

Comparison to Industry Standards

• The company is pursuing accelerated approval filings for emavusertib in PCNSL in the US and EU, a common strategy for orphan drug designated therapies in areas of high unmet medical need, similar to other biotech companies developing treatments for rare cancers.
• The planned clinical study of emavusertib in combination with a BTK inhibitor in R/R CLL aims to improve upon the current standard of care (BTKi), which often involves lifelong therapy, by potentially enabling complete remission or minimal residual disease (MRD) negativity and time-limited treatment. This directly compares to existing BTKi monotherapies like ibrutinib, acalabrutinib, or zanubrutinib.
• Discussions are underway for a head-to-head registrational trial of emavusertib versus gilteritinib in R/R AML, indicating a direct comparison against an approved FLT3 inhibitor, a standard treatment for this patient population.
• The ongoing triplet study evaluating emavusertib with venetoclax and azacitidine in frontline AML aligns with industry trends of developing multi-agent combination therapies to improve outcomes in aggressive leukemias, similar to combinations used by companies like AbbVie (venetoclax) and Bristol Myers Squibb (azacitidine).

Stakeholder Impact

• **Shareholders:** Potential for increased share value due to positive clinical trial progress and expanded pipeline, but also risk of dilution from future capital raises and uncertainty regarding long-term funding.
• **Patients:** Potential for new, more effective, and potentially time-limited treatment options for severe hematologic malignancies like PCNSL, CLL, AML, and MDS.
• **Employees:** Continued employment and opportunities within a company making clinical advancements, but potential for instability if future funding is not secured.
• **Creditors/Lenders:** The company's ability to secure future funding will directly impact its financial stability and ability to meet obligations.
• **Partners (Genentech/Roche, Aurigene):** Continued collaboration and potential for increased royalty revenues from Erivedge, and ongoing development of emavusertib.

Next Steps

• Provide updated data for R/R PCNSL patients from the TakeAim Lymphoma study later this year.
• Begin enrollment for a proof-of-concept clinical study of emavusertib in combination with a BTK inhibitor in R/R CLL patients later this year.
• Present data from the ongoing triplet study evaluating emavusertib, venetoclax, and azacitidine in frontline AML at the 67th ASH Annual Meeting in December.
• Continue discussions with clinical trial investigators and key opinion leaders on the design of a head-to-head registrational trial vs. gilteritinib in R/R AML.
• Continue discussions with clinical trial investigators and key opinion leaders on the design of a Phase 1/2 study in frontline high-risk MDS (hrMDS) in combination with azacitidine.
• Attend the Cantor Global Healthcare Conference 2025 from September 2-5, 2025.
• Attend the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025.

Key Dates

Recommendation

While Curis has demonstrated significant clinical progress with emavusertib, advancing towards accelerated approvals and expanding into new, high-potential indications like CLL, and has shown improved financial efficiency with reduced net losses and expenses, the company's cash runway is limited to Q1 2026. This necessitates substantial additional capital in the immediate term, introducing significant financial risk and potential for dilution. The positive clinical momentum is balanced by this critical funding need, suggesting a 'hold' recommendation until there is greater clarity on the company's long-term financing strategy and successful execution of its clinical milestones.

Keywords

Biotechnology, Oncology, Lymphoma, Leukemia, Emavusertib, IRAK4 inhibitor, PCNSL, CLL, AML, MDS, Clinical Trials, Drug Development, Orphan Drug, Nasdaq, CRIS